Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216365 | 1.00 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5220409 | 1.00 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5216030 | 1.00 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5216043 | 1.00 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL18980201 | 0.98 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25021936 | 0.87 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL52844 | 0.87 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30306973 | 0.87 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4669293 | 0.87 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1161371 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068354-A1 | SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-03 | — | — | WO | disclosed |
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| EP-4380919-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-117980290-A | Cyanopyridine and cyanopyrimidine BCL6 degrading agents | 达纳－法伯癌症研究所公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-111918651-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023015164-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| WO-2011143033-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026904-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| EP-1322596-B1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1322596-A1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6479518-B2 | PSYCHOLOGICAL DISORDERS | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | MERCK & CO., INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2002024629-A1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | NPY5R, NPY1R, NPY2R | CHRNB2 362/4885CHRNA4 225/4885CHRNB4 330/4885 |
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | BCL6, BCL6B, BCOR | CHRNB2 4716/4885CHRNA4 4693/4885CHRNB4 4701/4885 |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | CHRNB2 4677/4885CHRNA4 4789/4885CHRNB4 4805/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CHRNB2 4253/4885CHRNA4 4843/4885CHRNB4 4695/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | CHRNB2 4609/4885CHRNA4 4873/4885CHRNB4 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.